Abstract:Abstract INTRODUCTION: Liquid biopsy (LB) proved its clinical utility in advanced non-small cell lung cancer, but its role in early-stage disease is less clear. Here, we investigated the clinical utility of LB for molecular diagnosis in early-stage lung cancer and its correlation with cancer relapse. METHODS: This retrospective, monocentric study collected results from LB performed in patients (pts) with an early-stage lung cancer between January 2021 and May 2023, within the prospective STING study (NCT04932525). LBs were executed at different time points (before, after curative treatment, or under treatment), by using the Foundation One Liquid Dx panel. All patients had tissue molecular testing for at least EGFR, ALK and KRAS alterations. LB was considered positive (ctDNA+) if ≥ 1cancer-related alteration was identified and negative (ctDNA-) in the absence of somatic alterations or the presence of clonal hematopoiesis (CH) only. Disease-free survival (DFS) was calculated from diagnosis to cancer relapse or last follow-up, and correlated with LB results. RESULTS: A total of 52 pts were included and 52 LBs were conducted. Pts had a median age of 63 years, 40% (25/52) were females, and 84% (43/51) had a smoking history with a median pack-years of 37.5 [4-100]. Adenocarcinoma was the most common histology (48% 25/52), followed by squamous carcinoma (23% 12/52), undifferentiated (20% 10/52) and other hystologies (9% 5/52). Patients had stage I disease in 10% (5/52), stage II in 11% (6/52) and stage III in 79% (41/52). LB was performed before curative treatment in 35/52 (67%), after curative treatment in 6/52 (11.5%) and during curative treatment in 12/52 (23%). Overall, LB was positive in 57% (30/52) of cases: 63% (26/41) in stage III and 36% (4/11) in stage I/II. Major driver mutations identified in tissue were then found in 61.5% (8/13) of LBs. The concordance between LB and tissue findings was 100% in pts with ctDNA+ (7 KRAS, 4 EGFR, 1 ALK, 1 HER2 ampl). CH was present in 66.7% (20/30) of ctDNA+ LB and 47.8% (11/23) of ctDNA- LB. Median tumor mutational burden (TMB) in ctDNA+ LB was 5.5 mut/Mb, with 4 cases of TMB >16. Median follow-up was 12.6 months (mo). In pts with ctDNA+ versus ctDNA- LB, mDFS was 12.9 mo (95% 6.3-18.6) versus 27.7 mo (95%CI 12.7- NR), p=0.07, in the overall population and 12.9 mo (95%CI 7.8-19.2) versus 27.2 mo (12.7-NR) respectively, p=0.19, in pts with stage III disease. CONCLUSIONS: LB has informal results for molecular diagnosis in nearly half of pts with an early-stage lung cancer. The high frequency of CH may lead to LB misinterpretation as false positive and requires caution. The potential association of positive LB with earlier relapse requires further investigation in larger cohorts with a longer follow-up. Results will be updated by the time of meeting. Citation Format: Kristi Beshiri, Arianna Marinello, Damien Vasseur, Lodovica Zullo, Maria Virginia Sanchez Becerra, Arianna Pagliaro, Massimiliano Cani, Claudia Parisi, Pernelle Lavaud, Maxime Frelaut, Pamela Abdayem, Anas Gazzah, Angela Botticella, Antonin Levy, Cecile Le Pechoux, Olaf Mercier, Santiago Ponce, Fabrice Barlesi, David Planchard, Antonio Italiano, Benjamin Besse, Jordie Remon, Mihaela Aldea. Clinical utility of liquid biopsy in early stage lung cancer: A single institution experience [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 7490.

Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA

Is It Time to Incorporate Liquid Biopsy into High-Risk Cancer Surveillance Protocols in Li–Fraumeni Syndrome?

Multiple Germline Events Contribute to Cancer Development in Patients with Li-Fraumeni Syndrome

Cell-free DNA from germline TP53 mutation carriers reflect cancer-like fragmentation patterns

Abstract 3380: Use of liquid biopsy for detection of pathogenic variants in cell-free tumor DNA from patients with precursor lesions and colorectal cancer

Abstract 810: Enrichment and Screening of LFS Patients by Analyzing TP53 Germline Mutations of a Chinese Cancer Cohort

Abstract 7490: Clinical utility of liquid biopsy in early stage lung cancer: A single institution experience

Abstract 3448: A novel liquid biopsy lung cancer detection method using a coverage and fragment end motif machine learning analysis

Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection

Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets

CancerScreen: A Novel Ultrasensitive Liquid Biopsy for Early-Stage Cancer Detection by Ctdna Duplex Sequencing and Tissue of Origin Identification with Supervised Machine Learning.

Abstract 1533: Characterizing tumor-immune surveillance in Li-Fraumeni syndrome

Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA

Hematologic malignancies in Li–Fraumeni syndrome: A case report

Liquid biopsy and its role in an advanced clinical trial for lung cancer

Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer

A dual biomarker in non-small cell lung cancer that predicts Li Fraumeni syndrome : Lung cancer and Li Fraumeni

Abstract LB102: Triaging oral premalignant lesions: Plasma ultrashort cell-free DNA-based liquid biopsy approach

Ultra-short Cell-Free DNA Fragments Enhance Cancer Early Detection in a Multi-Analyte Blood Test Combining Mutation, Protein and Fragmentomics.

Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience

The Liquid Biopsy Consortium: Challenges and Opportunities for Early Cancer Detection and Monitoring